Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0960

View: 789 Download: 27 Crossref: 1

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 1122 Download: 52 Crossref: 1

Original Article

Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment

Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen

Received November 27, 2024 Accepted March 14, 2025

DOI: https://doi.org/10.3350/cmh.2024.1070 [Accepted]

View: 1229 Download: 96

Correspondence

Correspondence to editorial “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”

Rui Huang, Mindie H. Nguyen

Received April 29, 2025 Accepted May 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0478 [Accepted]

View: 124 Download: 1

Correspondence to editorial “Metabolic health in antiviral era of chronic hepatitis B”

Rui Huang, Mindie H. Nguyen

Received April 29, 2025 Accepted May 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0479 [Accepted]

View: 133 Download: 1

1 |

Viewed By 10962	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7667	MAFLD: How is it different from NAFLD?
Viewed By 5556	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5016	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4913	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 342	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 316	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search